THU0482 Evolution of comorbid fibromyalgia frequency in axial spondyloarthritis patients starting an anti-tnf agent, and correlation to anti-tnf efficacy. the predict-spa study. (15th June 2017)

• Record Type: Journal Article
• Authors: Perrot, S; Moltό, A; Etcheto, A; Boudersa, N; Claudepierre, P; Roux, N; Berenbaum, F; Martin, A; Sparsa, L; Coquerelle, P; Soubrier, M; Gossec, L; Dougados, M
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 388
• Page End: 389
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.4688
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Fibromyalgia (FM) is a frequent comorbid condition in axial spondyloarthritis (axSpA). It is not known how FM comorbidity may respond to the management of SpA, and especially to anti-TNF agents. Objectives: To evaluate the change of comorbid FM status of axSpA patients starting an anti-TNF treatment. Methods: A prospective multicenter national study involving 39 rheumatology centers in France, analyzing 519 patients with axSpA requiring anti-TNF therapy (ClinicalTrials.gov: NCT03039088 ). Patients were screened for FM with the FiRST questionnaire before and after 3 months of anti-TNF. Kappa coefficient was calculated to determine the agreement of the FiRST at M0 and M3. Response to anti-TNF (BASDAI50 response was compared according to positive screening for FM or not, at both time-points using chi2 tests. Results: Of the 519 enrolled pts, 504 (with complete data on the FiRST questionnaire) were analyzed at M3. A positive screening for comorbid FM was found in 192 pts (38%) at M0 and in 127 (25%) pts at M3. Correlation between FiRST at M0 and M3 was weak with a Kappa coefficient correlation of 0.4 [0, 3 - 0, 5]. Four groups were identified: group [+/+] with comorbid FM at M0 and M3: N=93 (18%; group [+/-] with comorbid FM at M0 but not at M3: N=99 (20%); group [-/-] without comorbid FM at M0 and M3: N=278 (55%); group [-/+] without comorbid FM at M0 but at M3: N=34 (7%) Changes in the status of comorbid FM (disappearance or appearance) was observed in 134 pts (26%). In the 193 pts with baseline comorbid FM, after 3 months of anti-TNF treatment, comorbid FM was no longer found in 99 (51%)%.Efficacy at M3 was significantly better, according to BASDAI 50, in patients without comorbid FM at M3 (Table). Conclusions: There is a high frequency of comorbid FM screened by the FiRST in active axSpA, decreased by 51%f after 3 months of anti-TNF treatments. Persistence of FM after 3 months of anti-TNF treatment is associated with lower anti-TNF response. Further studies are required to analyze the impact of screening FM before starting anti-TNF therapy in axSpA. References: Perrot S, et al. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain. 2010;150:250–6. Acknowledgements: This study was conducted thanks to an unrestricted grant from MSD. Disclosure of Interest: None declared